Vector Bioscience has developed an innovative RNAi delivery platform based on metal-organic frameworks (MOFs) designed to overcome critical barriers limiting RNA molecules’ therapeutic potential. Our technology ensures effective protection, precise targeted delivery, and efficient endosomal escape of synthetic RNA molecules, enabling potent and selective gene silencing. In this validation project, we aim to conduct comprehensive in vivo studies using a KRAS knockdown model to rigorously assess our platform’s stability, pharmacokinetic (PK) profile, biodistribution, and toxicology. By validating our platform’s effectiveness in safely and precisely silencing gene expression, this project will significantly advance RNA therapeutics, unlocking new personalised medicine opportunities and attracting strategic industry partnerships.